A dual-action ligand targeting both integrin αVβ3 and vascular endothelial growth factor receptors (VEGFRs), was synthesized via conjugation of a cyclic peptidomimetic αVβ3 Arg-Gly-Asp (RGD) ligand with a decapentapeptide. The latter was obtained from a known VEGFR antagonist by acetylation at the Lys13 side chain. Functionalization of the precursor ligands was carried out in solution and in the solid phase, affording two fragments: an alkyne VEGFR ligand and the azide integrin αVβ3 ligand, which were conjugated by click chemistry. Circular dichroism studies confirmed that both the RGD and VEGFR ligand portions of the dual-action compound substantially adopt the biologically active conformation. In vitro binding assays on isolated integrin αVβ3 and VEGFR-1 showed that the dual-action conjugate retains a good level of affinity for both its target receptors, although with one order of magnitude (10/20 times) decrease in potency. The dual-action ligand strongly inhibited the VEGF-induced morphogenesis in Human Umbilical Vein Endothelial Cells (HUVECs). Remarkably, its efficiency in preventing the formation of new blood vessels was similar to that of the original individual ligands, despite the worse affinity towards integrin αVβ3 and VEGFR-1. Two are better than one: A dual-action ligand, designed to target both integrin αVβ3 and vascular endothelial growth factor receptors (VEGFRs) and possibly block their "crosstalk", strongly inhibits the VEGF-stimulated morphogenesis in Human Umbilical Vein Endothelial Cells (HUVEC), preventing the formation of new blood vessels.
Synthesis, characterization, and biological evaluation of a dual-action ligand targeting αvβ3 integrin and VEGF receptors / S. Zanella, M. Mingozzi, A. Dal Corso, R. Fanelli, D. Arosio, M. Cosentino, L. Schembri, F. Marino, M. De Zotti, F. Formaggio, L. Pignataro, L. Belvisi, U. Piarulli, C. Gennari. - In: CHEMISTRYOPEN. - ISSN 2191-1363. - 4:5(2015 Oct), pp. 633-641. [10.1002/open.201500062]
Synthesis, characterization, and biological evaluation of a dual-action ligand targeting αvβ3 integrin and VEGF receptors
S. Zanella;M. Mingozzi;A. Dal Corso;R. Fanelli;L. Pignataro;L. Belvisi;C. Gennari
2015
Abstract
A dual-action ligand targeting both integrin αVβ3 and vascular endothelial growth factor receptors (VEGFRs), was synthesized via conjugation of a cyclic peptidomimetic αVβ3 Arg-Gly-Asp (RGD) ligand with a decapentapeptide. The latter was obtained from a known VEGFR antagonist by acetylation at the Lys13 side chain. Functionalization of the precursor ligands was carried out in solution and in the solid phase, affording two fragments: an alkyne VEGFR ligand and the azide integrin αVβ3 ligand, which were conjugated by click chemistry. Circular dichroism studies confirmed that both the RGD and VEGFR ligand portions of the dual-action compound substantially adopt the biologically active conformation. In vitro binding assays on isolated integrin αVβ3 and VEGFR-1 showed that the dual-action conjugate retains a good level of affinity for both its target receptors, although with one order of magnitude (10/20 times) decrease in potency. The dual-action ligand strongly inhibited the VEGF-induced morphogenesis in Human Umbilical Vein Endothelial Cells (HUVECs). Remarkably, its efficiency in preventing the formation of new blood vessels was similar to that of the original individual ligands, despite the worse affinity towards integrin αVβ3 and VEGFR-1. Two are better than one: A dual-action ligand, designed to target both integrin αVβ3 and vascular endothelial growth factor receptors (VEGFRs) and possibly block their "crosstalk", strongly inhibits the VEGF-stimulated morphogenesis in Human Umbilical Vein Endothelial Cells (HUVEC), preventing the formation of new blood vessels.File | Dimensione | Formato | |
---|---|---|---|
Gennari_Piarulli_ChemistryOpen_2015_633.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
734.53 kB
Formato
Adobe PDF
|
734.53 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.